Merus Labs International Inc. has entered into an agreement with Sanofi S.A. to acquire the rights to Surgestone, Provames, Speciafoldine, and Tredemine in France for about $24.8 million.
Surgestone and Provames are used in a variety of women’s health indications; Speciafoldine is used to treat macrocytic anemia; and Tredemine is tapeworm medicine.
"We have acquired nine established products over the last ten months and continue to leverage our scalable commercial platform in Europe," said Barry Fishman, Merus CEO.
The acquisition is expected to close during the second week in March 2016.
